CytoMed Therapeutics Limited
GDTC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5.7% | 90.9% | -51.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.1% | 93.1% | 174.9% | 89.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Income | -$1 | -$0 | -$1 | -$0 |
| % Margin | -483% | -483% | -2,348.6% | -366.3% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -834.7% | -834.7% | -2,055.1% | -511.6% |
| EPS | -0.075 | -0.071 | -0.093 | -0.048 |
| % Growth | -5.7% | 24.2% | -93.6% | – |
| EPS Diluted | -0.075 | -0.071 | -0.093 | -0.048 |
| Weighted Avg Shares Out | 12 | 12 | 12 | 12 |
| Weighted Avg Shares Out Dil | 12 | 12 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$0 | -$1 |
| % Margin | -760.9% | -760.9% | -920.4% | -472% |